Evidence map›Paper›PMID 12083460›Full record

ReviewAdvances in experimental medicine and biology2002

Interactions of flavones and other phytochemicals with adenosine receptors.

Kenneth A Jacobson, Stefano Moro, John A Manthey, Patrick L West, Xiao-Duo Ji

Abstract readReview
In one paragraph

Review in Advances in experimental medicine and biology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 85 citations in OpenAlex.

  1. Trial
  2. Utilization of Cannabidiol in Post-Organ-Transplant Care.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. A Potential Alternative against Neurodegenerative Diseases: Phytodrugs.Oxidative medicine and cellular longevity · 2016
    Review
  16. Flavonoid regulation of HCN2 channels.The Journal of biological chemistry · 2013
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes ofHealth, Bethesda, MD 20892-0810, USA. kajacobs@helix.nih.gov
Stefano Moro
John A Manthey
Patrick L West
Xiao-Duo Ji
National Institutes of Health · USNational Institute of Diabetes and Digestive and Kidney Diseases · USWinter Haven Hospital · US

Funding

Drugs that Act at Adenosine ReceptorsZ01DK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$854k
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDSZ01DK031115 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$577k
Intramural NIH HHS Z01 DK031117Intramural NIH HHS Z99 DA999999Intramural NIH HHS Z99 DK999999Intramural NIH HHS Z99 OD999999
6 · The paper itself

Abstract

Dietary flavonoids have varied effects on animal cells, such as inhibition of platelet binding and aggregation, inhibition of inflammation, and anticancer properties, but the mechanisms of these effects remain largely unexplained. Adenosine receptors are involved in the homeostasis of the immune, cardiovascular, and central nervous systems, and adenosine agonists/antagonists exert many similar effects. The affinity of flavonoids and other phytochemicals to adenosine receptors suggests that a wide range of natural substances in the diet may potentially block the effects of endogenous adenosine. We used competitive radioligand binding assays to screen flavonoid libraries for affinity and a computational CoMFA analysis of flavonoids to compare steric and electrostatic requirements for ligand recognition at three subtypes of adenosine receptors. Flavone derivatives, such as galangin, were found to bind to three subtypes of adenosine receptors in the microM range. Pentamethylmorin (Ki 2.65 microM) was 14- to 17-fold selective for human A3 receptors than for A1 and A2A receptors. An isoflavone, genistein, was found to bind to A1 receptors. Aurones, such as hispidol (Ki 350 nM) are selective A1 receptor antagonists, and, like genistein, are present in soy. The flavones, chemically optimized for receptor binding, have led to the antagonist, MRS 1067 (3,6-dichloro-2'-(isopropoxy)4'-methylflavone), which is 200-fold more selective for human A3 than A1 receptors. Adenosine receptor antagonism, therefore, may be important in the spectrum of biological activities reported for the flavonoids.

Indexed as

Purinergic P1 Receptor AntagonistsAnimalsComputer SimulationDietDrug DesignDrug Evaluation, PreclinicalFlavonoidsHumansHydrogen BondingHydrophobic and Hydrophilic InteractionsIsoflavonesMethylationModels, MolecularMolecular StructureRatsReceptors, Purinergic P13,6-dichloro-2'-isopropyloxy-4'-methylflavoneFlavonoidsIsoflavonesPurinergic P1 Receptor AntagonistsReceptors, Purinergic P1

Identifiers

PMID12083460
PMCPMC3429336
OpenAlexW1542102949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.